Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder
NCT ID: NCT01002326
Last Updated: 2016-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13 participants
INTERVENTIONAL
2009-06-30
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder
NCT00106223
Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder
NCT01453439
Internet-delivered Cognitive-behaviour Therapy for Child and Adolescent Body Dysmorphic Disorder
NCT06262412
Internet Cognitive Behavior Therapy (CBT) for Body Dysmorphic Disorder (BDD)
NCT01850433
Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD)
NCT00871143
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the first phase of this trial, we will develop the treatment manual, adapting the adult manual for use in a pediatric population. In the second phase of this trial we will test the effectiveness of the CBT treatment in 12 pediatric BDD patients. We intend to treat 12 children and adolescents with BDD. All patients will receive CBT. We will also examine treatment feasibility and acceptability (e.g., retention and reasons for treatment refusal and dropout, expectancy, and motivation), and we will explore predictors of outcome. Therapeutic progress will be broadly assessed with measures of beliefs, behaviors, mood, functioning, and quality of life before, during, and after treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cognitive-Behavioral Therapy
Cognitive-Behavioral Therapy
20 sessions of Cognitive-Behavioral Therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive-Behavioral Therapy
20 sessions of Cognitive-Behavioral Therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Total score of at least 24 on the 12-item BDD-YBOCS, adolescent version, which includes a score of at least 2 on item 1 (1-3 hours/day of preoccupation with the perceived defect)
* Score of at least moderate on the Clinical Global Impressions of Severity (CGI-Severity)
* Score of \< 60 on the Child Global Assessment Scale (C-GAS)
* Ability to communicate meaningfully with the investigators and competent to provide written assent; both parental informed consent and adolescent assent must be obtained
Exclusion Criteria
* Recent (within the past 6 months) suicide attempt, or suicidal ideation as indicated by a K-SADS score of 4 or higher that is active or warrants consideration of hospitalization
* Need for inpatient or partial hospital treatment
* Current psychotherapy and failure to benefit from ten or more sessions of previous CBT treatment
* Participants can be receiving psychotropic medication, but they must be on a stable dose for 2 months prior to the study baseline assessment and maintain this dosage throughout the course of the study
10 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sabine Wilhelm
Director, OCD and Related Disorders Program at Massachusetts General Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sabine Wilhelm, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Jennifer Greenberg, Psy.D.
Role: STUDY_DIRECTOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008P002270
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.